By targeting these receptors directly, Tanaka and colleagues hoped to shut down lupus pathology at the earliest point in the process, preventing interferon release and the subsequent autoimmune ...

The sBLA is supported by data from the randomized, double-blind, placebo-controlled phase 3 REGENCY study (ClinicalTrials.gov Identifier: NCT04221477), which included patients with International ...